Page 2428 - Williams Hematology ( PDFDrive )

2399
2398 Index Index 2399

adverse effects, 579 pernicious. See Pernicious anemia (PA) hemochromatosis, 642–643
for anemia of primary myelofibrosis, 1328 in pregnancy, 120 knockout, 153
for aplastic anemia, 526 preoperative, 2378 transgenic, 153
deficiency, anemia and, 560 prevalence of, 134, 134t Anion exchanger (AE1), 663t, 664
erythropoietic effects, 560, 879, 880f in primary myelofibrosis, 1328 Anisocytosis, 21
for Fanconi anemia, 529 of protein deficiency (kwashiorkor), 654 Anistreplase, 2313, 2313t
for paroxysmal nocturnal hemoglobinuria, sideroblastic. See Sideroblastic anemias ANK1i, 666
578–579 of starvation, 654 Ankyrin, 663t, 666, 666f, 670t, 671–672
Anemia, 503–506 trace metal deficiency, 653–654 Annexin A2, 1973f, 1974, 1976, 2237, 2305t,
in acute lymphoblastic leukemia, 1509 unexplained, 134, 136 2309
in acute myelogenous leukemia, 1381 vitamin-deficiency, 651–653. See also Annexin A5 anticoagulant shield, 2236, 2236f
in alcoholism, 654–655 specific vitamins Annexin A5 resistance assay, 2243–2244
aplastic. See Aplastic anemia Anemia of chronic kidney disease Anorexia, history of, 5
from blood donation, 629–630 clinical features, 552 Anorexia nervosa, 654
of chronic disease, 549. See also Anemia of epidemiology, 550 Anosmia, history of, 5
inflammation (AI) iron deficiency and, 637 Anthracyclines, 327–328. See also specific
of chronic kidney disease. See Anemia of laboratory features, 552 drugs
chronic kidney disease pathophysiology, 549, 550f for acute lymphoblastic leukemia, 1515
of chronic liver disease, 636 therapy, course, and prognosis, 554t, 555 for acute myelogenous leukemia, 1394–
classification, 506, 507–508t Anemia of inflammation (AI), 549–555 1396, 1395t
clonal, 1277 clinical features, 552 adverse effects, 327–328, 1520
congenital dyserythropoietic. See conditions associated with, 550t for anaplastic large cell lymphoma, 1699
Congenital dyserythropoietic definition and history, 549 for intravascular large B-cell lymphoma,
anemias (CDAs) differential diagnosis, 553–554 1635–1636
consultative approach to, 42 epidemiology, 550 for mantle cell lymphoma, 1655
cow’s milk, 630 etiology and pathogenesis, 550–552, 551f mechanism of action, 327
of critical illness, 549 vs. iron deficiency, 636 pharmacology, 327–328
differential diagnosis, 42 laboratory features, 552–553, 553f, 553t for primary cutaneous diffuse large B-cell
dilution, 554, 742 therapy, course, and prognosis, 554–555, lymphoma, leg type, 1637
of endocrine disorders, 559–561 554t resistance to, 319t
factitious, 630 Anesthesia Antiangiogenesis agents, for acute
Fanconi. See Fanconi anemia for marrow aspiration, 28 myelogenous leukemia, 1404
hemolytic. See Hemolytic anemia platelet function and, 2079 Antiannexin A2 antibodies, 1976
of hemolytic disease, 637 in sickle cell disease, 773 Anti-B glycoprotein antibody assays, 2242
2
in HIV infection. See Human Aneuploidy, 175t Antibiotics. See also specific drugs
immunodeficiency virus (HIV) Aneurysm, formation of, 1975, 1975f for α-heavy-chain disease, 1808
infection, anemia in Angina pectoris, 5, 2295–2297 anthracycline. See Anthracyclines
in Hodgkin lymphoma, 1610 Angiogenesis, 279 platelet effects, 2078
hypoplastic, 637 fibrinolysis and, 2311 Antibodies
of hypothyroidism, 559, 637 in myelodysplastic syndromes, 1353 dendritic cells and, 309
iatrogenic, 629 in primary myelofibrosis, 1321 erythrocyte. See Erythrocyte antibodies
of inflammation. See Anemia of regulation by hypoxia, 504f to human leukocyte antigens, 2356
inflammation (AI) Angiogenin, 1449 to neutrophil antigens, 2358–2359
iron-deficiency. See Iron deficiency Angiography, for pulmonary embolism, to platelet antigens, 2361–2362
with marrow infiltration. See Marrow, 2271–2272, 2272f reaginic, 1162
infiltration Angioimmunoblastic T-cell lymphoma Antibody-dependent cellular cytotoxicity
from metastatic invasion of marrow, (AITL), 1498t, 1598, 1694–1695, (ADCC), 344–345, 1645
553–554 1694t, 1695t, 1697–1698 Antibody identification, 2336
newborn, 103, 849 Angioma, tufted, 2014 Antibody screening, 2336, 2349.
pathophysiology and manifestations, Angiotensin II, 1879 See also Erythrocyte antibodies
503–506 Anhydrotic ectodermal dysplasia with Anticardiolipin antibody, 2101f
cardiac output, 505 immunodeficiency caused by Anticardiolipin antibody assays, 2242
oxygen transport, 503–505, 504f, 505f NEMO mutations, 1215 Anti-CCR4 monoclonal antibody.
pulmonary function, 505 Anidulafungin, 385, 388t, 389 See Mogamulizumab
red cell production, 505–506, 505f Animal models Anti-CD20 monoclonal antibody.
tissue hypoxia, 506 eosinophilic disease, 951 See Rituximab

Kaushansky_index_p2393-2506.indd 2399 9/21/15 3:21 PM